公开(公告)号：US20220024918A1

公开(公告)日：2022-01-27

申请号：US17368712

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20230086884A1

公开(公告)日：2023-03-23

申请号：US17822450

申请日：2022-08-26

Applicant: YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

Inventor： Byoungmoon LEE ,  Hyunjoo LEE ,  Gyu Jin LEE ,  Su Bin CHOI ,  Sol PARK ,  Heejun KIM ,  Misong KIM ,  Young Ae YOON ,  Kwan Hoon HYUN ,  Tae Kyun KIM ,  Jae Young SIM ,  Marian C. BRYAN ,  Scott KUDUK ,  James Campbell ROBERTSON

IPC: C07D401/14

Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US20210147368A1

公开(公告)日：2021-05-20

申请号：US17104557

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223844A1

公开(公告)日：2020-07-16

申请号：US16712673

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20240174636A1

公开(公告)日：2024-05-30

申请号：US18551894

申请日：2022-03-22

Applicant: YUHAN CORPORATION

Inventor： Gyu-Jin LEE ,  Eui-Chul LEE ,  Sol PARK ,  Dong-Hoon LEE ,  Su-Hwa KIM ,  Jong-Suk PARK ,  Ho-Woong KANG ,  Hyun-Sik YUN

IPC: C07D401/12 ,  A61K31/4709 ,  A61K31/517 ,  C07D215/18 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04

CPC classification number: C07D401/12 ,  A61K31/4709 ,  A61K31/517 ,  C07D215/18 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04

Abstract: Provided are a compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof not only has excellent inhibitory activity against indoleamine 2,3-dioxygenase (IDO) but also exhibits remarkably high in vivo exposure upon oral administration and therefore the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with IDO.

公开(公告)号：US20200223827A1

公开(公告)日：2020-07-16

申请号：US16712660

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Eui Chul LEE ,  Sol PARK ,  Hyok Jun CHO ,  Cheol Hee LIM ,  So Young KIM ,  Hyun Ho CHOI ,  Da Na JEONG ,  Na Yeon YANG ,  Na Ry HA

IPC: C07D403/10 ,  C07D249/12 ,  C07D403/04 ,  C07D401/04 ,  C07D405/10 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20230044255A1

公开(公告)日：2023-02-09

申请号：US17368738

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Eui Chul LEE ,  Sol PARK ,  Hyok Jun CHO ,  Cheol Hee LIM ,  So Young KIM ,  Hyun Ho CHOI ,  Da Na JEONG ,  Na Yeon YANG ,  Na Ry HA

IPC: C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20210317110A1

公开(公告)日：2021-10-14

申请号：US17208887

申请日：2021-03-22

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223808A1

公开(公告)日：2020-07-16

申请号：US16721020

申请日：2019-12-19

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20190322655A1

公开(公告)日：2019-10-24

申请号：US16359985

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).